Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
Andrew B. GerryJoseph P. SandersonManoj SainiBarbara TavanoRoslin Y. DoctaNicholas J. PumphreyMiguel MarotoE.C. BorderAlan BennettGwendolyn Binder-SchollTom HoldichLini PanditeRafael G. AmadoBent K. Jakobsen
Abstract
Meeting abstracts Preclinical safety testing for adoptive immunotherapies utilising T cell receptor-(TCR) engineered T cells relies on stringent target validation and a robust pre-clinical specificity testing strategy. Specific safety concerns include on-target off-tumour toxicity and off-target
Metrics
Citation History
Topics
Related Documents
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
Joseph P. SandersonDarragh CrowleyGuy E. WiedermannLaura L. QuinnKatherine L. CrosslandHelen M. TunbridgeTerri V CornforthChristopher S. BarnesTina AhmedKaren HoweManoj SainiRachel J.M. AbbottVictoria E. AndersonBarbara TavanoMiguel MarotoAndrew B. Gerry
Abstract 2564: Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10
E.C. BorderJoseph P. SandersonThomas WeissensteinerNatalie HylandTom HoldichFrancine BrophyRafael G. AmadoAndrew B. GerryNicholas J. Pumphrey
Abstract 2562: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4
Joana M. SenraPamela VillalobosBarbara MinoLuisa M. SolisCarmen BehrensJoseph P. SandersonManoj SainiAndrew B. GerryNicholas J. PumphreyMiguel MarotoBoris SepesiPatrick HwuDavid S. HongElizabeht A. MittendorfGeorge BlumenscheinIgnacio I. WistubaGwendolyn Binder-SchollRafael G. Amado
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
E.C. BorderJoseph P. SandersonThomas WeissensteinerAndrew B. GerryNicholas J. Pumphrey
MAGE-A3 Specific T-Cell Receptor Adoptive Cell Transfer of Multiple Myeloma
Jeesun ParkZhong ShiMichelle KrogsgaardAmitabha Mazumder